AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02040571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop
Description: A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
Study NCT00912899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noscapine HCl
Description: Escalating doses given twice per day
Study NCT02896777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer embryo from pH 7.20±0.02 on either Day 3 or day 5/6
Description: Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.20±0.02.
Study NCT02896777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer embryo from pH 7.3±0.02 either Day 3 or day 5/6
Description: Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.3±0.02.
Study NCT02896777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer embryo from pH of 7.4±0.02 on either Day 3 or day 5/6
Description: Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.4±0.02 from day 0 to 5/6
Study NCT03433365 — intervention group
Intervention type: OTHER
Intervention: MRD analysis
Description: To collect 2 samples for MRD analysis in patients treated with Lenalidomide
Study NCT04625452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBCC+5A's+GS
Description: It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information.
Study NCT00567736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disci/Rhus toxicodendron comp.®
Description: s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
Study NCT00567736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Description: s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
Study NCT00865098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients receive Cetuximab at an initial dose of 400 mg/m\^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m\^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
Study NCT03384706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT looks at the impact the traumatic event has had on your life and helps you to examine and change unhelpful thoughts and feelings related to the event, yourself, others and the world.~CPT will be conducted in 5-15, 60 minute sessions held once or twice a week.
Study NCT03384706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART)
Description: ART, like CPT also involves processing thoughts and feelings related to the event, but does this in a different way relying more on visualization or imagination rather than talking.~ART will be conducted in 5-15, 60 minute sessions held once or twice a week.
Study NCT00792727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen Patch
Description: 2 topical patches applied once daily for 28 days
Study NCT00792727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: 2 topical placebo patches applied once daily for 28 days
Study NCT00865631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg tablets, single dose (1 tablet)
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study NCT00865631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 400 mg capsules, single dose (2 capsules)
Description: B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
Study NCT00865631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg tablets, single dose (1 tablet)
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions
Study NCT02040571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open Loop
Description: The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.~In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.~Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants.
Study NCT02760017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. forficata
Study NCT02760017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04108013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
Study NCT04108013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Paclitaxel-albumin
Description: In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
Study NCT02568683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: VCR administered intravenously
Study NCT03875014 — intervention group
Intervention type: DEVICE
Intervention: surgery with implant for hip fracture
Description: hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
Study NCT00971737 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic GM-CSF-secreting breast cancer vaccine
Description: Given intradermally
Study NCT00971737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic GM-CSF-secreting breast cancer vaccine
Description: Given intradermally
Study NCT00971737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00971737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00971737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT02893527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized coaching
Description: personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
Study NCT00006604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Study NCT03064308 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Programme
Description: Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
Study NCT04442269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
Study NCT04442269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT02848066 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample(10cc) collection
Description: In both groups, serum haptoglobins to be collected and analyzed
Study NCT06440187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+ nivolumab
Description: Gemcitabine+ nivolumab q 2wks
Study NCT00411398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namenda/Memantine
Description: 5mg tablets, 1-4 tabs by mouth per day
Study NCT01546324 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Maternal blood draw at approximately 8-17 weeks gestation.
Study NCT01589614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: Tablet, 6mg, single
Study NCT01589614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804 + erythromycin
Description: PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
Study NCT00882089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contura catheter
Description: Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
Study NCT01627886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate sodium
Description: Ibandronate sodium Tablets 150 mg
Study NCT01627886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate sodium
Description: Ibandronate sodium Tablets 150 mg
Study NCT01233544 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBRT or RFA
Description: Patients are allocated to one of the two arms in a 1:1 randomization
Study NCT01233544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT or RFA
Description: Patients are allocated to one of the two arms in a 1:1 randomization
Study NCT01623063 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopy
Description: hysteroscopy with guided biopsies
Study NCT01623063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: hysteroscopy with guided biopsies
Study NCT02148848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Take risedronate 35 mg orally every week
Study NCT01935453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant hGM-CSF Herpes Simplex Virus Injection
Study NCT03419182 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction internal Fixation
Description: A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture.
Study NCT03419182 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction Internal Fixation with Total Hip Arthroscopy
Description: A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture, and replaces the cartilage and bone of the greater trochanter with prosthetic components.
Study NCT01673126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
Study NCT01673126 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
Study NCT01329861 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Internet-based cognitive behavioural treatment
Description: Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
Study NCT04445948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 milligrams Oral Tablet
Description: Proton Pump inhibitor
Study NCT04445948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1000 milligrams tablets
Description: Penicillin derivative antibiotic
Study NCT00891436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate nasal spray
Description: 2 sprays each nostril every morning for 2 weeks
Study NCT00891436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: 2 sprays each nostril every morning for 2 weeks
Study NCT02164214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept Treatment
Study NCT02164214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept Treatment
Study NCT02624609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control without pomegranate juice
Description: Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
Study NCT04445948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500 milligrams Tablets
Description: Macrolide antibiotic
Study NCT01284855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antivenom
Description: Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
Study NCT01284855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antivenom
Description: Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
Study NCT03919487 — intervention group
Intervention type: PROCEDURE
Intervention: Back to back colonoscopy
Description: After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
Study NCT02182167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV N-acetylcysteine (NAC)
Study NCT02624609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test with pomegranate juice
Description: The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
Study NCT02182167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT02202980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study NCT00474604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: A scan will be performed.
Study NCT00474604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diffusion-weighted magnetic resonance imaging
Description: A scan will be performed.
Study NCT04445948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetroNIDAZOLE 500 milligrams Oral Tablet
Description: Antiprotozoal
Study NCT04445948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin Bovine sachets 200 milligrams
Description: a protein found naturally in milk from humans and cows
Study NCT00474604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: A scan will be performed.
Study NCT00474604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: A scan will be performed.
Study NCT00474604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance spectroscopic imaging
Description: A scan will be performed.
Study NCT04711213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Dose 1
Description: Dexamethasone ophthalmic suspension dose 1
Study NCT00006604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Administered as 100 mg capsules or oral solution.
Study NCT00474604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: magnetic resonance spectroscopic imaging
Description: A scan will be performed.
Study NCT04301245 — intervention group
Intervention type: OTHER
Intervention: Educational program
Description: The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment.
Study NCT02135406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19 T cells
Study NCT03358160 — intervention group
Intervention type: BEHAVIORAL
Intervention: Action discrimination tasks.
Description: The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
Study NCT02059330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75mg
Description: In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Study NCT02059330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Study NCT02059330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 100mg
Description: In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Study NCT02059330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
Study NCT02059330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
Study NCT04154826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-7
Description: weekly intra-muscular (IM) administration
Study NCT04953416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1565nm non ablative fractional laser
Description: The ResurFX module contains Erbium:Glass Fiber Laser Technology with wavelength of 1565 nm, which is transferred to the ResurFX handpiece via a fiber.
Study NCT01312181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HealthCall and Motivational Interviewing
Description: Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
Study NCT01312181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing (MI)
Description: The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
Study NCT01312181 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV/AIDS health education
Description: The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.